Novo's combination diabetes therapy Xultophy launched in U.S.

In its 1Q17 earnings, Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said it had launched Xultophy (IDegLira) insulin degludec/liraglutide in the U.S. to treat Type II diabetes and that the product is now available nationwide. The wholesale acquisition cost (WAC) is $953.18 for a package of five prefilled pens. Each 3 mL pen contains 100 units of insulin degludec and 3.6 mg liraglutide per mL. The recommended starting dose is 16 units of insulin degludec and 0.58 mg liraglutide once daily...